10 results match your criteria: "Hospital Universitario Vithas Madrid La Milagrosa[Affiliation]"
Radiat Oncol
December 2024
Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background/aim: Current approaches for locally advanced rectal cancer (LARC) typically recommend neoadjuvant chemoradiotherapy (nCRT) with 5-fluorouracil (5FU) or its oral analogs followed by surgery as the standard of care. However, the question of whether intensifying concurrent chemotherapy by adding oxaliplatin to the 5FU-based backbone can yield better outcomes remains unresolved. This study aimed to investigate the benefits of incorporating oxaliplatin into fluoropyrimidine-based chemoradiotherapy (CRT) to increase locoregional control and survival.
View Article and Find Full Text PDFRev Esp Cir Ortop Traumatol
November 2024
Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Vithas Madrid La Milagrosa, Madrid, Spain.
Cancer Med
October 2024
Department of Radiation Oncology, GenesisCare, Hospital Universitario Vithas Madrid La Milagrosa, Madrid, Spain.
Introduction: Historically, multimodal therapeutic strategies involving preoperative chemoradiotherapy (CRT), surgery, and adjuvant chemotherapy (CT) have been employed to treat locally advanced rectal cancer (LARC). Total Neoadjuvant Therapy (TNT) is showing promise in improving outcomes. Despite its benefits, the optimal sequencing within TNT-whether induction chemotherapy should precede or follow chemoradiotherapy-remains a critical question.
View Article and Find Full Text PDFRev Esp Cir Ortop Traumatol
July 2024
Hospital Universitario 12 de Octubre, Madrid, España; Hospital Universitario Vithas Madrid La Milagrosa, Madrid, España.
Mov Disord Clin Pract
September 2024
Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.
World J Clin Oncol
April 2024
Department of Radiation Oncology, GenesisCare - Hospital Universitario Vithas Madrid La Milagrosa, Madrid 28010, Spain.
In this editorial, we proceed to comment on the article by Chua , addressing the management of metastatic lateral pelvic lymph nodes (mLLN) in stage II/III rectal cancer patients below the peritoneal reflection. The treatment of this nodal area sparks significant controversy due to the strategic differences followed by Eastern and Western physicians, albeit with a higher degree of convergence in recent years. The dissection of lateral pelvic lymph nodes without neoadjuvant therapy is a standard practice in Eastern countries.
View Article and Find Full Text PDFJ Clin Med
April 2024
Synaptia Institute of Neurosciencies, Hospital Universitario Vithas Madrid La Milagrosa, 28010 Madrid, Spain.
This exploratory study evaluated the presence of sensitization-associated and neuropathic-like symptoms and identified their association with pressure sensitivity, pain, and disability in patients with cervical dystonia (CD). Thirty-one patients with CD (74.2% women, age: 61.
View Article and Find Full Text PDFOncology
July 2024
Department of Radiation Oncology, GenesisCare, Hospital Universitario Vithas Madrid La Milagrosa, Madrid, Spain.
Background: For the management of locally advanced rectal cancer (LARC), initial treatment with neoadjuvant chemoradiotherapy followed by surgery and chemotherapy in selected patients is considered one of the recommended options by the main international clinical guidelines. Nonetheless, the administration of all chemotherapy before definitive treatment (total neoadjuvant therapy [TNT]) is an optimal alternative with a growing level of evidence that must be evaluated in multidisciplinary boards. This review summarizes the available data and controversies in this scenario.
View Article and Find Full Text PDFIntern Emerg Med
September 2023
Pediatrics Department, Clinical Research Unit, Hospital Universitario Vithas Madrid La Milagrosa, Fundación Vithas, Madrid, Spain.
Intern Emerg Med
April 2023
Pediatrics Department, Clinical Research Unit, Hospital Universitario Vithas Madrid La Milagrosa, Fundación Vithas. Madrid, Madrid, Spain.
The significant impact of COVID-19 worldwide has made it necessary to develop tools to identify patients at high risk of severe disease and death. This work aims to validate the RIM Score-COVID in the SEMI-COVID-19 Registry. The RIM Score-COVID is a simple nomogram with high predictive capacity for in-hospital death due to COVID-19 designed using clinical and analytical parameters of patients diagnosed in the first wave of the pandemic.
View Article and Find Full Text PDF